7.15
price up icon3.32%   0.23
 
loading
Cybin Inc stock is traded at $7.15, with a volume of 591.85K. It is up +3.32% in the last 24 hours and down -7.50% over the past month. Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$6.92
Open:
$6.97
24h Volume:
591.85K
Relative Volume:
1.54
Market Cap:
$168.67M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-34.42
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+1.27%
1M Performance:
-7.50%
6M Performance:
-21.34%
1Y Performance:
-29.61%
1-Day Range:
Value
$6.86
$7.17
1-Week Range:
Value
$6.3637
$7.1901
52-Week Range:
Value
$4.81
$13.88

Cybin Inc Stock (CYBN) Company Profile

Name
Name
Cybin Inc
Name
Phone
908 764 8385
Name
Address
100 King Street West, Suite 5600, Toronto
Name
Employee
38
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CYBN's Discussions on Twitter

Compare CYBN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CYBN
Cybin Inc
7.15 163.24M 0 -52.07M -44.93M -0.2077
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Cybin Inc Stock (CYBN) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated Guggenheim Buy
Nov-19-21 Downgrade Maxim Group Buy → Hold

Cybin Inc Stock (CYBN) Latest News

pulisher
Aug 19, 2025

Is Now a Good Time to Reenter Cybin Inc.Portfolio Gains Summary & Consistent Income Trade Ideas - mustnews.co.kr

Aug 19, 2025
pulisher
Aug 19, 2025

Can Cybin Inc. Rally Enough to Break EvenStock Surge & AI Powered Buy and Sell Recommendations - classian.co.kr

Aug 19, 2025
pulisher
Aug 19, 2025

Cybin Inc. Moves Into Bullish Territory Based on MACDEarnings Overview Summary & Fast Exit and Entry Strategy Plans - newsyoung.net

Aug 19, 2025
pulisher
Aug 19, 2025

Cybin Inc. Reports Strong Shareholder Participation in 2025 Annual Meeting - citybuzz -

Aug 19, 2025
pulisher
Aug 19, 2025

H.C. Wainwright reiterates Buy rating on Cybin stock, maintains $150 target - Investing.com

Aug 19, 2025
pulisher
Aug 18, 2025

Cybin's Strategic Advancements and Financial Positioning Drive Buy Rating - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Announces Shareholder Meeting Results and Strategic Developments - TipRanks

Aug 18, 2025
pulisher
Aug 18, 2025

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Announces Results of Annual Meeting of Shareholders - Business Wire

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Inc. shares rise 2.17% after-hours following the Annual Meeting of Shareholders. - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Inc.'s Strategic Positioning in the Psychedelic Therapy Market: A Catalyst for Shareholder Value Creation - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin’s Strategic Advancements and Financial Positioning Drive Buy Rating - TipRanks

Aug 18, 2025
pulisher
Aug 18, 2025

Transcript : Cybin Inc.Shareholder/Analyst Call - MarketScreener

Aug 18, 2025
pulisher
Aug 18, 2025

Why Cybin Inc. stock attracts strong analyst attentionJuly 2025 Final Week & Daily Profit Focused Screening - classian.co.kr

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Inc. stock momentum explained2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser

Aug 18, 2025
pulisher
Aug 18, 2025

Cybin Posts Q1 2026 Loss of -$0.54 EPS; Market Reacts with Mixed Short-Term Optimism - AInvest

Aug 18, 2025
pulisher
Aug 17, 2025

Using data tools to time your Cybin Inc. exit2025 Top Gainers & AI Enhanced Execution Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Heatmap Data Shows High Activity in Cybin Inc. SectorRisk Management & Free Weekly Watchlist of Top Performers - newsyoung.net

Aug 17, 2025
pulisher
Aug 17, 2025

How Cybin Inc. stock performs during market volatilityJuly 2025 Trends & Community Consensus Picks - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Cybin Earnings Report (2026 Q1): Negative Net Income, Weak Margins, and Mixed Post-Earnings Market Signals - AInvest

Aug 17, 2025
pulisher
Aug 17, 2025

Intrinsic Value of Cybin Inc. Stock: Is It Undervalued or Overvalued2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Top Risks to Consider Before Buying Cybin Inc. StockBond Market & Real-Time Market Sentiment Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Risk adjusted return profile for Cybin Inc. analyzedJuly 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Does Cybin Inc. fit your quant trading modelWall Street Watch & Verified Momentum Stock Ideas - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

Cybin Inc. recovery potential after sell offInsider Selling & Reliable Breakout Forecasts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Earnings visualization tools for Cybin Inc.Weekly Stock Summary & Weekly High Potential Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Cybin stock price target cut to $150 at H.C. Wainwright - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Cybin Inc. Reports Q2 2025 Financial Results with Asset Growth - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Real time social sentiment graph for Cybin Inc.2025 Price Targets & Advanced Swing Trade Entry Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

What’s next for Cybin Inc. stock priceQuarterly Earnings Report & Expert Curated Trade Ideas - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Key resistance and support levels for Cybin Inc.Portfolio Update Summary & Safe Capital Investment Plans - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Cybin reports Q1 results - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

Is Cybin Inc. stock overvalued or fairly pricedBreakout Watch & Reliable Price Breakout Signals - newsyoung.net

Aug 15, 2025
pulisher
Aug 14, 2025

Psychedelic Stock Earnings: atai Life Sciences, Cybin Report Q1 Results - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Which companies are leading the development of psychedelic wellness products? - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Cybin Inc. Common Shares (NYSE:CYBN) Stock Quote - FinancialContent

Aug 14, 2025
pulisher
Aug 14, 2025

Trend Reversal Possible in Cybin Inc. Charts IndicateWeekly Investment Summary & Fast Entry and Exit Trade Plans - sundaytimes.kr

Aug 14, 2025
pulisher
Aug 14, 2025

Psychedelic: atai Life Sciences, Cybin report earnings results - TipRanks

Aug 14, 2025
pulisher
Aug 14, 2025

MACD Cross Could Confirm Trend in Cybin Inc.2025 Technical Overview & AI Forecast for Swing Trade Picks - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

Cybin Reports Q1 FY26 Financials, Advances Clinical Programs, and Secures $50M Financing Agreement. - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

Cybin Reports Important Progress on Key Milestones and First Qua - GuruFocus

Aug 13, 2025
pulisher
Aug 13, 2025

Cybin Reports Q1 FY26 Financial Results, Advances Key Milestones in Psychedelic Therapies - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results - Bluefield Daily Telegraph

Aug 13, 2025
pulisher
Aug 13, 2025

Cybin Inc. Amends Convertible Note Agreement with High Trail - TipRanks

Aug 13, 2025
pulisher
Aug 12, 2025

Cybin (OTCMKTS:CYBN) Shares Down 2.6% – Should You Sell? - Defense World

Aug 12, 2025
pulisher
Aug 12, 2025

What momentum shifts mean for Cybin Inc.Swing Entry Insight With Forecast Accuracy - Newser

Aug 12, 2025
pulisher
Aug 08, 2025

Cybin gains Irish Medicines Board approval for major depressive disorder trial - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - BioSpace

Aug 08, 2025
pulisher
Aug 07, 2025

Cybin Inc. shares rise 1.13% intraday after receiving approval to initiate EMBRACE trial in Europe. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Psychedelic: Cybin receives European approval for EMBRACE study - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Cybin receives European approval for EMBRACE trial - TipRanks

Aug 07, 2025

Cybin Inc Stock (CYBN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):